vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and Village Farms International, Inc. (VFF). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $12.2M, roughly 1.6× Village Farms International, Inc.). Village Farms International, Inc. runs the higher net margin — 19.9% vs -90.7%, a 110.6% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs 31.5%).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
Grafton Village Cheese Company is a cheesemaker in the town of Grafton in the U.S. state of Vermont. The company produces hand-crafted aged cheddar cheese.
NAMS vs VFF — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $12.2M |
| Net Profit | $-17.4M | $2.4M |
| Gross Margin | — | — |
| Operating Margin | -186.1% | — |
| Net Margin | -90.7% | 19.9% |
| Revenue YoY | 740.1% | 31.5% |
| Net Profit YoY | 55.5% | 128.2% |
| EPS (diluted) | $-0.15 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.2M | ||
| Q3 25 | — | $66.7M | ||
| Q2 25 | $19.1M | $59.9M | ||
| Q1 25 | — | $77.1M | ||
| Q4 24 | $12.8M | — | ||
| Q3 24 | $29.1M | $54.9M | ||
| Q2 24 | — | $53.6M | ||
| Q1 24 | — | $78.1M |
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $10.2M | ||
| Q2 25 | $-17.4M | $26.5M | ||
| Q1 25 | — | $-6.7M | ||
| Q4 24 | $-92.2M | — | ||
| Q3 24 | $-16.6M | $-820.0K | ||
| Q2 24 | — | $-23.5M | ||
| Q1 24 | — | $-2.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | 47.9% | ||
| Q2 25 | — | 37.3% | ||
| Q1 25 | — | 14.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 24.8% | ||
| Q2 24 | — | 25.4% | ||
| Q1 24 | — | 19.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | 23.3% | ||
| Q2 25 | -186.1% | 20.8% | ||
| Q1 25 | — | -8.0% | ||
| Q4 24 | -338.5% | — | ||
| Q3 24 | -85.9% | 3.8% | ||
| Q2 24 | — | -43.5% | ||
| Q1 24 | — | -3.0% |
| Q4 25 | — | 19.9% | ||
| Q3 25 | — | 15.3% | ||
| Q2 25 | -90.7% | 44.2% | ||
| Q1 25 | — | -8.7% | ||
| Q4 24 | -721.7% | — | ||
| Q3 24 | -57.2% | -1.5% | ||
| Q2 24 | — | -43.9% | ||
| Q1 24 | — | -3.7% |
| Q4 25 | — | $0.01 | ||
| Q3 25 | — | $0.08 | ||
| Q2 25 | $-0.15 | $0.24 | ||
| Q1 25 | — | $-0.06 | ||
| Q4 24 | $-0.91 | — | ||
| Q3 24 | $-0.18 | $-0.01 | ||
| Q2 24 | — | $-0.21 | ||
| Q1 24 | — | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | $81.2M |
| Total DebtLower is stronger | — | $33.7M |
| Stockholders' EquityBook value | $778.5M | $299.9M |
| Total Assets | $815.1M | $423.1M |
| Debt / EquityLower = less leverage | — | 0.11× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $81.2M | ||
| Q3 25 | — | $82.6M | ||
| Q2 25 | $739.2M | $60.0M | ||
| Q1 25 | — | $15.1M | ||
| Q4 24 | $834.2M | — | ||
| Q3 24 | $422.7M | $28.7M | ||
| Q2 24 | — | $29.7M | ||
| Q1 24 | — | $26.7M |
| Q4 25 | — | $33.7M | ||
| Q3 25 | — | $34.6M | ||
| Q2 25 | — | $39.1M | ||
| Q1 25 | — | $39.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $43.3M | ||
| Q2 24 | — | $44.4M | ||
| Q1 24 | — | $46.1M |
| Q4 25 | — | $299.9M | ||
| Q3 25 | — | $295.4M | ||
| Q2 25 | $778.5M | $284.3M | ||
| Q1 25 | — | $248.3M | ||
| Q4 24 | $757.5M | — | ||
| Q3 24 | $378.9M | $274.4M | ||
| Q2 24 | — | $275.2M | ||
| Q1 24 | — | $296.2M |
| Q4 25 | — | $423.1M | ||
| Q3 25 | — | $418.4M | ||
| Q2 25 | $815.1M | $403.7M | ||
| Q1 25 | — | $377.1M | ||
| Q4 24 | $864.6M | — | ||
| Q3 24 | $439.2M | $417.8M | ||
| Q2 24 | — | $425.4M | ||
| Q1 24 | — | $458.4M |
| Q4 25 | — | 0.11× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.14× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | 0.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | — |
| Free Cash FlowOCF − Capex | $-37.8M | — |
| FCF MarginFCF / Revenue | -197.2% | — |
| Capex IntensityCapex / Revenue | 0.5% | 90.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $24.4M | ||
| Q2 25 | $-37.7M | — | ||
| Q1 25 | — | $-6.4M | ||
| Q4 24 | $-37.5M | — | ||
| Q3 24 | $-12.5M | $4.3M | ||
| Q2 24 | — | $5.7M | ||
| Q1 24 | — | $-50.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $22.6M | ||
| Q2 25 | $-37.8M | — | ||
| Q1 25 | — | $-8.9M | ||
| Q4 24 | $-37.5M | — | ||
| Q3 24 | $-12.6M | $1.5M | ||
| Q2 24 | — | $4.8M | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | 33.9% | ||
| Q2 25 | -197.2% | — | ||
| Q1 25 | — | -11.6% | ||
| Q4 24 | -293.5% | — | ||
| Q3 24 | -43.2% | 2.7% | ||
| Q2 24 | — | 9.0% | ||
| Q1 24 | — | -2.5% |
| Q4 25 | — | 90.8% | ||
| Q3 25 | — | 2.7% | ||
| Q2 25 | 0.5% | 4.6% | ||
| Q1 25 | — | 3.3% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | 5.1% | ||
| Q2 24 | — | 1.6% | ||
| Q1 24 | — | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.39× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NAMS
Segment breakdown not available.
VFF
| International Sales | $8.7M | 71% |
| Cannabis United States Segment | $3.4M | 27% |
